New Risk • Jun 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (327% accrual ratio). Market cap is less than US$10m (₹750.7m market cap, or US$7.88m). Minor Risk Revenue is less than US$5m (₹472m revenue, or US$5.0m). Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 254% over the past three years. Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹25.74 (vs ₹2.33 loss in FY 2025) Full year 2026 results: EPS: ₹25.74 (up from ₹2.33 loss in FY 2025). Revenue: ₹481.7m (up 98% from FY 2025). Net income: ₹175.7m (up ₹191.6m from FY 2025). Profit margin: 37% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Annonce • May 22
Phaarmasia Limited to Report Q4, 2026 Results on May 29, 2026 Phaarmasia Limited announced that they will report Q4, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹93.49, the stock trades at a trailing P/E ratio of 3.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 253% over the past three years. New Risk • Apr 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹607.2m market cap, or US$6.56m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₹449m revenue, or US$4.9m). Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹88.94, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 240% over the past three years. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹75.20, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹99.12, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 304% over the past three years. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: ₹23.84 (vs ₹1.02 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹23.84 (up from ₹1.02 loss in 3Q 2025). Revenue: ₹162.1m (up 243% from 3Q 2025). Net income: ₹162.7m (up ₹169.7m from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth. Annonce • Feb 02
Phaarmasia Limited to Report Q3, 2026 Results on Feb 06, 2026 Phaarmasia Limited announced that they will report Q3, 2026 results on Feb 06, 2026 Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₹49.08, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 57% over the past three years. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹2.54 (vs ₹0.94 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹2.54 (up from ₹0.94 loss in 2Q 2025). Revenue: ₹166.9m (up 182% from 2Q 2025). Net income: ₹17.4m (up ₹23.8m from 2Q 2025). Profit margin: 10% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Annonce • Nov 07
Phaarmasia Limited to Report Q2, 2026 Results on Nov 14, 2025 Phaarmasia Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Annonce • Sep 03
Phaarmasia Limited, Annual General Meeting, Sep 25, 2025 Phaarmasia Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time. New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (₹180.9m market cap, or US$2.06m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (₹230m revenue, or US$2.6m). Reported Earnings • Aug 12
First quarter 2026 earnings released: EPS: ₹0.40 (vs ₹0.40 in 1Q 2025) First quarter 2026 results: EPS: ₹0.40 (in line with 1Q 2025). Revenue: ₹71.9m (down 13% from 1Q 2025). Net income: ₹2.70m (down 2.2% from 1Q 2025). Profit margin: 3.8% (up from 3.3% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annonce • Aug 09
Phaarmasia Limited to Report Q1, 2026 Results on Aug 11, 2025 Phaarmasia Limited announced that they will report Q1, 2026 results on Aug 11, 2025 Reported Earnings • May 29
Full year 2025 earnings released: ₹2.33 loss per share (vs ₹0.76 loss in FY 2024) Full year 2025 results: ₹2.33 loss per share (further deteriorated from ₹0.76 loss in FY 2024). Revenue: ₹251.2m (down 18% from FY 2024). Net loss: ₹15.9m (loss widened 207% from FY 2024). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Annonce • May 23
Phaarmasia Limited to Report Q4, 2025 Results on May 28, 2025 Phaarmasia Limited announced that they will report Q4, 2025 results on May 28, 2025 Reported Earnings • Feb 18
Third quarter 2025 earnings released: ₹1.02 loss per share (vs ₹0.83 loss in 3Q 2024) Third quarter 2025 results: ₹1.02 loss per share (further deteriorated from ₹0.83 loss in 3Q 2024). Revenue: ₹49.1m (down 3.4% from 3Q 2024). Net loss: ₹6.99m (loss widened 24% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Annonce • Feb 11
Phaarmasia Limited to Report Q3, 2025 Results on Feb 14, 2025 Phaarmasia Limited announced that they will report Q3, 2025 results on Feb 14, 2025 New Risk • Nov 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹317.0m market cap, or US$3.75m). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (₹293m revenue, or US$3.5m). New Risk • Nov 06
New major risk - Revenue and earnings growth Earnings have declined by 46% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹353.4m market cap, or US$4.20m). Minor Risk Revenue is less than US$5m (₹293m revenue, or US$3.5m). Reported Earnings • Nov 06
Second quarter 2025 earnings released: ₹0.94 loss per share (vs ₹0.24 loss in 2Q 2024) Second quarter 2025 results: ₹0.94 loss per share (further deteriorated from ₹0.24 loss in 2Q 2024). Revenue: ₹61.5m (down 29% from 2Q 2024). Net loss: ₹6.42m (loss widened 295% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Annonce • Nov 01
Phaarmasia Limited to Report Q2, 2025 Results on Nov 05, 2024 Phaarmasia Limited announced that they will report Q2, 2025 results on Nov 05, 2024 Annonce • Sep 02
Phaarmasia Limited, Annual General Meeting, Sep 24, 2024 Phaarmasia Limited, Annual General Meeting, Sep 24, 2024, at 14:30 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.40 (vs ₹0.39 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.40 (up from ₹0.39 loss in 1Q 2024). Revenue: ₹84.4m (up 23% from 1Q 2024). Net income: ₹2.76m (up ₹5.42m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Aug 06
Phaarmasia Limited to Report Q1, 2025 Results on Aug 12, 2024 Phaarmasia Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Reported Earnings • May 27
Full year 2024 earnings released: ₹0.76 loss per share (vs ₹1.84 loss in FY 2023) Full year 2024 results: ₹0.76 loss per share (improved from ₹1.84 loss in FY 2023). Revenue: ₹312.5m (up 14% from FY 2023). Net loss: ₹5.18m (loss narrowed 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Annonce • May 19
Phaarmasia Limited to Report Q4, 2024 Results on May 25, 2024 Phaarmasia Limited announced that they will report Q4, 2024 results at 12:15 PM, Indian Standard Time on May 25, 2024 New Risk • Apr 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.5m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 59% per year over the past 5 years. Market cap is less than US$10m (₹272.9m market cap, or US$3.27m). Minor Risk Revenue is less than US$5m (₹281m revenue, or US$3.4m). Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹0.83 loss per share (vs ₹0.87 loss in 3Q 2023) Third quarter 2024 results: ₹0.83 loss per share (improved from ₹0.87 loss in 3Q 2023). Revenue: ₹52.1m (down 34% from 3Q 2023). Net loss: ₹5.64m (loss narrowed 4.6% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Annonce • Feb 06
Phaarmasia Limited to Report Q3, 2024 Results on Feb 13, 2024 Phaarmasia Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Reported Earnings • Nov 18
Second quarter 2024 earnings released: ₹0.24 loss per share (vs ₹0.43 loss in 2Q 2023) Second quarter 2024 results: ₹0.24 loss per share (improved from ₹0.43 loss in 2Q 2023). Revenue: ₹88.4m (up 33% from 2Q 2023). Net loss: ₹1.63m (loss narrowed 44% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Market cap is less than US$10m (₹172.2m market cap, or US$2.07m). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Annonce • Nov 08
Phaarmasia Limited to Report Q2, 2024 Results on Nov 14, 2023 Phaarmasia Limited announced that they will report Q2, 2024 results on Nov 14, 2023 Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023) First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.42 loss in 1Q 2023) First quarter 2024 results: ₹0.39 loss per share (improved from ₹0.42 loss in 1Q 2023). Revenue: ₹70.2m (up 31% from 1Q 2023). Net loss: ₹2.65m (loss narrowed 6.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Annonce • Aug 08
Phaarmasia Limited to Report Q1, 2024 Results on Aug 14, 2023 Phaarmasia Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jul 10
Full year 2023 earnings released: ₹1.84 loss per share (vs ₹2.27 loss in FY 2022) Full year 2023 results: ₹1.84 loss per share (improved from ₹2.27 loss in FY 2022). Revenue: ₹274.9m (up 60% from FY 2022). Net loss: ₹12.6m (loss narrowed 19% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Buying Opportunity • Jul 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 9.8%. The fair value is estimated to be ₹29.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Annonce • Jun 14
Phaarmasia Limited, Annual General Meeting, Jul 10, 2023 Phaarmasia Limited, Annual General Meeting, Jul 10, 2023. Annonce • May 19
Phaarmasia Limited to Report Q4, 2023 Results on May 25, 2023 Phaarmasia Limited announced that they will report Q4, 2023 results on May 25, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: ₹0.87 loss per share (vs ₹1.07 loss in 3Q 2022) Third quarter 2023 results: ₹0.87 loss per share (improved from ₹1.07 loss in 3Q 2022). Revenue: ₹80.6m (up 108% from 3Q 2022). Net loss: ₹5.91m (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 142 percentage points per year, which is a significant difference in performance. Annonce • Feb 14
Phaarmasia Limited to Report Q3, 2023 Results on Feb 13, 2023 Phaarmasia Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Nov 08
Phaarmasia Limited to Report Q2, 2023 Results on Nov 14, 2022 Phaarmasia Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Annonce • Sep 07
Phaarmasia Limited, Annual General Meeting, Sep 27, 2022 Phaarmasia Limited, Annual General Meeting, Sep 27, 2022, at 16:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the company for the financial year ended 31st March, 2022, along with Notes, the Reports of the Board of Directors and the Auditors thereon; to appoint directors; to reappoint M/s. Sathuluri& Co., Chartered Accountants (Firm Registration No. 006383S)as statutory auditors of the Company; and to discuss other matters. Annonce • Aug 03
Phaarmasia Limited to Report Q1, 2023 Results on Aug 12, 2022 Phaarmasia Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Annonce • May 21
Phaarmasia Limited to Report Q4, 2022 Results on May 27, 2022 Phaarmasia Limited announced that they will report Q4, 2022 results on May 27, 2022 Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ajit Jamkhandikar was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹1.07 loss per share (down from ₹0.04 profit in 3Q 2021). Revenue: ₹39.5m (down 18% from 3Q 2021). Net loss: ₹7.28m (down ₹7.54m from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. Annonce • Feb 04
Phaarmasia Limited to Report Q3, 2022 Results on Feb 10, 2022 Phaarmasia Limited announced that they will report Q3, 2022 results on Feb 10, 2022 Reported Earnings • Nov 11
Second quarter 2022 earnings released: ₹1.04 loss per share (vs ₹0.12 profit in 2Q 2021) The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2022 results: Revenue: ₹54.5m (up 22% from 2Q 2021). Net loss: ₹7.10m (down ₹7.93m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹33.45, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment improved over the past week After last week's 23% share price gain to ₹30.60, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improved over the past week After last week's 26% share price gain to ₹30.70, the stock trades at a trailing P/E ratio of 69.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹31.55, the stock trades at a trailing P/E ratio of 68.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 6.8% over the past three years. Reported Earnings • Jun 29
Full year 2021 earnings released: EPS ₹0.46 (vs ₹0.79 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹207.9m (down 15% from FY 2020). Net income: ₹3.12m (down 42% from FY 2020). Profit margin: 1.5% (down from 2.2% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹33.00, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 100% over the past year. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improved over the past week After last week's 23% share price gain to ₹36.75, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.9% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹23.50, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹0.04 (vs ₹0.02 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹48.2m (down 29% from 3Q 2020). Net income: ₹255.0k (up 104% from 3Q 2020). Profit margin: 0.5% (up from 0.2% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Annonce • Feb 05
Phaarmasia Limited to Report Q3, 2021 Results on Feb 12, 2021 Phaarmasia Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Dec 29
New 90-day high: ₹33.30 The company is up 20% from its price of ₹27.65 on 30 September 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₹33.30, the stock is trading at a trailing P/E ratio of 35.5x, up from the previous P/E ratio of 30.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 25%. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 15% share price gain to ₹27.15, the stock is trading at a trailing P/E ratio of 29x, up from the previous P/E ratio of 25.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total return to shareholders over the past three years is a loss of 11%. Is New 90 Day High Low • Nov 24
New 90-day low: ₹24.70 The company is down 36% from its price of ₹38.40 on 26 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. 
